501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

Richard L Hengel; Timothy E Ritter; Ramesh V Nathan; Lucinda J Van Anglen; Claudia P Schroeder; Stephen Marcella; Kevin W Garey

doi:10.1093/OFID/OFY210.510

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

Richard L Hengel
, Timothy E Ritter
, Ramesh V Nathan
, Lucinda J Van Anglen
, Claudia P Schroeder
, Stephen Marcella
, Kevin W Garey

Atlanta ID Group, Atlanta, Georgia
Luminal Research Division, Texas Digestive Disease Consultants, Southlake, Texas
Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, California
Healix Infusion Therapy, Sugar Land, Texas
Merck & Co.
University of Houston

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Open Forum Infectious Diseases
Volume	5
DOIs	https://doi.org/10.1093/OFID/OFY210.510
State	Published - Oct 4 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1093/OFID/OFY210.510License: Unspecified

Cite this

@article{57a3255282724a6c88b5d14b5f543765,

title = "501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers",

author = "Hengel, \{Richard L\} and Ritter, \{Timothy E\} and Nathan, \{Ramesh V\} and \{Van Anglen\}, \{Lucinda J\} and Schroeder, \{Claudia P\} and Stephen Marcella and Garey, \{Kevin W\}",

note = "Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile Background : Bezlotoxumab (BEZ) was approved in October 2016 for the prevention of recurrent C. difficile (rCDI) infection in patients (pts) receiving standard-of-care (SoC) antibiotic therapy for active CDI who are at high risk for CDI recurrence.",

year = "2018",

month = oct,

day = "4",

doi = "10.1093/OFID/OFY210.510",

language = "American English",

volume = "5",

journal = "Open Forum Infectious Diseases",

}

TY - JOUR

T1 - 501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

AU - Hengel, Richard L

AU - Ritter, Timothy E

AU - Nathan, Ramesh V

AU - Van Anglen, Lucinda J

AU - Schroeder, Claudia P

AU - Marcella, Stephen

AU - Garey, Kevin W

N1 - Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile Background : Bezlotoxumab (BEZ) was approved in October 2016 for the prevention of recurrent C. difficile (rCDI) infection in patients (pts) receiving standard-of-care (SoC) antibiotic therapy for active CDI who are at high risk for CDI recurrence.

PY - 2018/10/4

Y1 - 2018/10/4

UR - https://idsa.confex.com/idsa/2018/webprogram/Paper69223.html

U2 - 10.1093/OFID/OFY210.510

DO - 10.1093/OFID/OFY210.510

M3 - Article

VL - 5

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

ER -

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

Disciplines

Access to Document

Other files and links

Cite this